Neutrophil dynamics in response to chemotherapy and G-CSF

Journal of Theoretical Biology

Volumn 293, Issue , 2012, Pages 111-120

  Zhuge, Changjing ^a,b   Lei, Jinzhi ^a   Mackey, Michael C ^b  

^a TSINGHUA UNIVERSITY   (China)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Mathematical model; Neutropenia; Resonance; Timing

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

CHEMOTHERAPY; NUMERICAL MODEL;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL; NEUTROPENIA; NEUTROPHILS;

EID: 80155183667     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.10.017     Document Type: Article

References (37)

1. Apostu R., Mackey M.C. Understanding cyclical thrombocytopenia: a mathematical modeling approach. J. Theor. Biol. 2008, 251:297-316.
2. Bennett C.L., Weeks J.A., Somerfield M.R., et al. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J. Clin. Oncol. 1999, 17:3676-3681.
3. Bernard S., Pujo-Menjouet L., Mackey M.C. Analysis of cell kinetics using a cell division marker: mathematical modeling of experimental data. Biophys. J. 2003, 84:3414-3424.
4. Bernard S., Bélair J., Mackey M.C. Oscillations in cyclical neutropenia: new evidence based on mathematical modeling. J. Theor. Biol. 2003, 223:283-298.
5. Brooks, G., Bélair, J., Zhuge, C., Lei, J., Mackey, M.C. Influence of pharmacokinetics on the effects of chemotherapy and G-CSF in neutrophil regulation, in preparation.
6. Butler R.D., Waites T.M., Lamar R.E., Hainsworth J.D., Greco F.A., Johnson DH. Timing of G-CSF administration during intensive chemotherapy for breast cancer (abstract). Am. Soc. Clin. Oncol. 1992, 11:1411.
7. Clark O.A., Lyman G.H., Castro A.A., Clark L.G., Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J. Clin. Oncol. 2005, 23:4198-4214.
8. Colijn C., Mackey M.C. A mathematical model of hematopoiesis: I. Periodic chronic myelogenous leukemia. J. Theor. Biol. 2005, 237:117-132.
9. Colijn C., Mackey M.C. A mathematical model of hematopoiesis: II. Cyclical neutropenia. J. Theor. Biol. 2005, 237:133-146.
10. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2003, 100:228-237.
11. Dancey J.T., Deubelbeiss K.A., Harker L.A., Finch C.A. Neutrophil kinetics in man. J. Clin. Invest. 1976, 58:705-715.
12. Engel C., Scholz M., Loeffler M.A. Computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood 2004, 104:2323-2331.
13. Foley C., Mackey M.C. Mathematical model for G-CSF administration after chemotherapy. J. Theor. Biol. 2009, 257:27-44.
14. Friberg L.E., Henningsson A., Maas H., Nguyen L., Karlsson M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 2002, 20:4713-4721.
15. Fukuda M., Nakato M., Kinoshita A., et al. Optimal timing of G-CSF administration in patients receiving chemotherapy for non-small cell lung cancer (NSCLC) (abstract). Am. Soc. Clin. Oncol. 1993, 12:1549.
16. Hannun Y. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997, 89:1845-1853.
17. Haurie C., Dale D.C., Rudnicki R., Mackey M.C. Modeling complex neutrophil dynamics in the grey collie. J. Theor. Biol. 2000, 24:505-519.
18. Hearn T., Haurie C., Mackey M.C. Cyclical neutropenia and the peripherial control of white blood cell production. J. Theor. Biol. 1998, 192:167-181.
19. Holmes F.A., O'Shaughnessy J.A., Vukelja S., Jones S.E., Shogan J., Savin M., Glaspy J., Moore M., Meza L., Wiznitzer I., Neumann T.A., Hill L.R., Liang B.C. Blinded, randomized, multicenter study to evaluate single administration Pegfilgrastim once per cycle versus daily Filgrastim as an adjunct to chemotherapy in patients with high-risk Stage II or Stage III/IV breast cancer. J. Clin. Oncol. 2002, 20:727-731.
20. Israels L.G., Israels E.D. Mechanisms in Hematology 2002, Core Health Services Inc.
21. Kennedy B.J. Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. Blood 1970, 35:751-760.
22. Koumakis G., Vassilomanolakis M., Barbounis V., Hatzichristou E., Demiri S., Plataniotis G., Pamouktsoglou F., Efremidis A.P. Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 1999, 56:28-35.
23. Lei J., Mackey M.C. Multistability in an age-structured model of hematopoiesis: cyclical neutropenia. J. Theor. Biol. 2011, 270:143-153.
24. Mackey M.C. Mathematical models of hematopoietic cell replication and control. The Art of Mathematical Modeling: Case Studies in Ecology, Physiology and Biofluids 1996, 149-178. Prentice-Hall. H. Othmer, F. Adler, M. Lewis, J. Dallon (Eds.).
25. Mackey M.C., Aprikyan A.A.G., Dale D.C. The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans. Cell. Prolif. 2003, 36:27-34.
26. Mackey M.C. Cell kinetic status of hematopoietic stem cells. Cell Prolif. 2001, 34:71-83.
27. Marshall J.E. Control of Time-Delay Systems 1979, The Institution of Electrical Engineers, London.
28. Meisenberg B.R., Davis T.A., Melaragno A.J., Stead R., Monroy R.L. A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy. Blood 1992, 79:2267-2272.
29. Morstyn G., Campbell L., Lieschke G., Layton J.E., Maher D., O'Connor M., Green M., Sheridan W., Vincent M., Alton K., Souza L., McGrath K., Fox R.M. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J. Clin. Oncol. 1989, 7:1554-1562.
30. Price T.H., Chatta G.S., Dale D.C. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996, 88:335-340.
31. Rahman Z., Esparza-Guerra L., Yap H., Fraxchini G., Bodey G., Hortobagyi G. Chemotherapy-induced neutrophenia and fever in patients with metastasic breast carcinoma receiving salvage chemotherapy. Cancer 1997, 79:1150-1157.
32. Scholz M., Engel C., Loeffler M. Modelling human granulopoiesis under poly-chemotherapy with G-CSF support. J. Math. Biol. 2005, 50:397-439.
33. Shochat E., Rom-Kedar V., Segel L.A. G-CSF control of neutrophil dynamics in the blood. Bull. Math. Biol. 2007, 69:2299-2338.
34. Skeel, R.T. (Ed.), 2007. Handbook of Cancer Chemotherapy, 7th ed. Lippincott Williams & Wilkins.
35. Thatcher N., Girling D.J., Hopwood P., Sambrook R.J., Qian W., Stephens R.J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulogyte colony-stimulating factor support: results of a British medical research council multicenter randomized trial. J. Clin. Oncol. 2000, 18:395-404.
36. Tjan-Heijnen V.C.G., Wagener D.J.T., Postmus P.E. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann. Oncol. 2002, 13:1519-1530.
37. Vainstein V., Ginosara Y., Shohamb M., Ranmara D., Ianovskib A., Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J. Theor. Biol. 2005, 234:311-327.